Updated: European Commission authorizes Novavax's updated Covid vaccine
Following the European Medicines Agency’s human medicines committee (CHMP) recommendation, the European Commission has authorized for use Novavax’s adapted Nuvaxovid booster vaccine for preventing the Omicron XBB.1.5 subvariant of the coronavirus in adults and adolescents 12 years of age and older.
The decision was based on non-clinical data showing that Novavax’s updated vaccine induced functional immune responses against the XBB.1.5, XBB.1.16 and XBB.2.3 variants.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.